Irbesartan reduced heart failure in ACTIVE-I trial of patients with atrial fibrillation.
D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D000077405:Irbesartan; D013777:Tetrazoles / Q000627:therapeutic use*
D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan